DentaBiome Claims Evaluated: 2026 Oral Postbiotic Consumer Warning Report Issued




DentaBiome Claims Evaluated: 2026 Oral Postbiotic Consumer Warning Report Issued

A 2026 consumer warning report examining DentaBiome’s oral postbiotic formula, how FabM acid-lock and 30-second kitchen method claims relate to published research, the ingredient research context commonly cited in this category, the published pricing structure, and which details consumers may wish to verify through publicly available materials

Tallmadge, OH, March 17, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dental advice. All product details described below are based on publicly available information from the official DentaBiome website and should be verified directly before any purchasing decision.

In this report, the term “effectiveness” refers strictly to how DentaBiome’s marketing language describes potential outcomes. It does not indicate that the finished product has been clinically proven effective, and no published clinical trial appears to evaluate DentaBiome as a proprietary formula.

This consumer warning report provides a 2026 analysis of the oral postbiotic supplement category and DentaBiome’s position within it. It covers how DentaBiome’s formula and marketing claims relate to published research, what the ingredient-level evidence shows under controlled study conditions, and the product details available through the official DentaBiome website at getdentabiome.com.

If you’ve been researching oral postbiotics for dental support online, you’ve almost certainly come across DentaBiome. The product has generated strong consumer interest across wellness forums, supplement discussion sites, and social media — particularly among adults over 35 who deal with recurring gum sensitivity, persistent bad breath, or frustration with dental outcomes despite consistent brushing and flossing routines.

DentaBiome, a chewable tablet supplement built around postbiotic strains and botanical compounds, has become one of the products frequently associated with the phrase “30-second kitchen method” for oral health. With that visibility come real questions. Is the postbiotic approach to oral care grounded in published research? How do DentaBiome’s “FabM acid-lock” claims relate to the scientific literature? And what does publicly available research actually say about the individual ingredients involved?

This report covers the DentaBiome formula, its published ingredient research context, pricing structure, and the details consumers should be aware of before making a purchasing decision through the official product page and published terms.

Current product details, pricing, and terms are available by viewing the current DentaBiome offer (official DentaBiome page).

Individual results vary. Dietary supplements are not substitutes for professional dental care, balanced nutrition, or regular oral hygiene. Consult a qualified healthcare provider or dentist before starting any new supplement regimen.

What Is DentaBiome

DentaBiome is a dietary supplement marketed as an oral postbiotic formula delivered through a Berry Frost-flavored chewable tablet. It is positioned as a once-daily chewable designed to deliver postbiotic compounds directly to the oral cavity rather than the digestive tract — which is the basis for the chewable format over a traditional capsule.

DentaBiome is manufactured in the United States in an FDA-registered, GMP-certified facility. Each batch undergoes third-party inspections for purity and potency. The supplement is listed as vegan, dairy-free, non-GMO, and non-habit forming.

DentaBiome is sold directly through the official website at getdentabiome.com. The return address is listed as Adem Naturals, 285 Northeast Ave, Tallmadge, OH 44278. Payments are processed through ClickBank as the authorized retailer.

Each chewable tablet contains a proprietary blend of postbiotic strains and natural compounds. The key strains include Lactobacillus plantarum (dual-strain complex), Lactobacillus salivarius, and Lactobacillus rhamnosus, along with what the formula includes as a “BioFresh Clean Complex” enzyme blend, xylitol, purple carrot powder, and cranberry extract.

The FabM Acid-Lock: How DentaBiome’s Central Claim Relates to Published Research

Published research describes FabM in controlled laboratory settings involving genetically engineered bacterial strains. Application of this mechanism to consumer supplements has not been established in clinical trials. The following section provides context on the published research behind the FabM concept and how it relates to DentaBiome’s ingredient approach.

DentaBiome’s central marketing narrative connects the supplement to a mechanism involving an enzyme called FabM and its role in creating what is described as an “acid-lock” around harmful oral bacteria. The product page references research showing that disabling the FabM gene made harmful bacteria dramatically more vulnerable to destruction.

FabM is a real enzyme studied in published peer-reviewed research. The FabM gene encodes a trans-2, cis-3-decenoyl-ACP isomerase enzyme in Streptococcus mutans, the primary bacterial species linked to dental caries. Published research from the University of Rochester Medical Center, led by Robert G. Quivey Jr. and colleagues, demonstrated that FabM is responsible for producing unsaturated fatty acids in the bacterial membrane that help S. mutans survive acidic environments.

A 2004 study published in the Journal of Bacteriology (Fozo and Quivey, 2004) showed that when researchers genetically deleted the FabM gene from S. mutans, the resulting mutant bacteria became extremely sensitive to low pH conditions. A subsequent 2007 study demonstrated that the FabM-deficient strain exhibited fewer and less severe carious lesions in a rodent model and was poorly transmissible from host to host.

Separately, research described via the University of Rochester has characterized the magnitude of vulnerability — noting that without FabM, S. mutans becomes approximately 10,000 times more susceptible to acid damage. That figure has been referenced in connection with the FabM research program and appears in supplementary commentary from the research team.

These are real findings on a real enzyme — but there are important distinctions worth understanding before connecting that research to any specific consumer product.

The studies above involved genetic deletion of the FabM gene in laboratory settings using engineered bacterial strains. They did not test any dietary supplement, postbiotic compound, or oral health product. The mechanism studied — complete gene knockout — is fundamentally different from consuming a chewable tablet containing postbiotic ingredients. No published research has demonstrated that any dietary supplement, including DentaBiome, can replicate the effects of genetically disabling FabM in live oral bacteria inside a human mouth.

DentaBiome’s marketing materials reference the FabM research as context for the product’s positioning. However, the connection between published FabM gene-deletion research and the effects of the specific postbiotic strains in this supplement has not been established through independent product-level clinical trials.

Consumers encountering terms such as “DentaBiome FabM,” “acid-lock oral health,” “DentaBiome oral postbiotic,” or similar marketing-related search phrases should understand that marketing claims referencing institutional research describe gene-level laboratory findings, not product-level clinical outcomes verified through independent testing of the finished supplement.

This report does not conclude whether DentaBiome has or lacks utility as an oral health support formula. It focuses on providing context for how the performance-related marketing language relates to the published research landscape.

Postbiotics vs. Probiotics for Oral Health: What the Research Landscape Shows

DentaBiome’s formula is built around postbiotics rather than probiotics — and this distinction does have a basis in published scientific literature, though the practical implications for a consumer supplement are worth examining carefully.

Postbiotics are defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as non-viable bacterial preparations or their metabolic byproducts that confer health benefits on the host. Unlike probiotics, which are live microorganisms, postbiotics are the compounds that beneficial bacteria produce — including antimicrobial peptides, organic acids, and protective enzymes.

A 2025 systematic review published in Clinical and Experimental Dental Research evaluated the current evidence regarding postbiotics and dental caries prevention. The review concluded that postbiotics offer a promising approach by targeting cariogenic bacteria and modulating the oral microbiome, with advantages over probiotics in terms of stability, safety, and ease of incorporation into oral care products. However, the same review noted significant limitations, including that most evidence comes from in vitro studies that may not capture the full complexity of the oral cavity, short follow-up durations, and variability in strains and formulations studied.

A comprehensive 2023 review published in Frontiers in Cellular and Infection Microbiology similarly acknowledged that while postbiotics show effects comparable to probiotics in addressing pathogens such as S. mutans, more animal studies and human clinical trials are needed to conclusively prove their effectiveness for oral health applications.

The published research supports the concept that postbiotic compounds can influence oral bacteria under controlled conditions. Whether a specific consumer supplement delivers those compounds at concentrations sufficient to produce meaningful effects in the oral cavity is a separate question — one that requires product-level testing rather than extrapolation from strain-level or in vitro research.

DentaBiome Ingredient Profile: What the Product Page Discloses

The following ingredients are included in the DentaBiome formula. Published research referenced in the sections below relates to individual compounds or strains studied under controlled conditions rather than the finished product as formulated.

The DentaBiome product page lists the following ingredient categories:

Dual-Strain L. Plantarum Complex: These two synergistic postbiotic strains are positioned as the core of the DentaBiome formula. The product page describes this complex as targeting the FabM acid-lock mechanism, supporting enamel remineralization, and neutralizing plaque acids. L. plantarum strains have been studied in published research for antimicrobial activity against oral pathogens, though published studies have used specific characterized strains at defined concentrations — details that the DentaBiome label does not individually disclose.

L. Salivarius: Described on the product page as a “construction blocker” postbiotic that shuts down bacterial construction genes and reduces volatile sulfur compounds associated with bad breath. Published research on L. salivarius has examined its potential effects on oral microbial balance, though outcomes depend on strain selection and dosage.

L. Rhamnosus: Positioned in DentaBiome’s marketing as a “gum guardian” that inhibits gum disease bacteria and creates a protective tooth shield. A 2023 study published in Frontiers in Bioscience-Landmark examined antimicrobial effects of postbiotic mediators derived from L. rhamnosus GG on S. mutans under laboratory conditions. These findings are strain-specific and laboratory-based.

BioFresh Clean Complex: Described on the DentaBiome website as a revolutionary enzyme blend that shatters the acid-lock barrier. The product page references specific percentage reductions in harmful bacteria at defined timepoints. These figures are presented in marketing materials and do not appear to be sourced from published peer-reviewed clinical trials testing the finished DentaBiome product.

Xylitol: A well-studied sugar alcohol with published research supporting its role in oral health. Multiple peer-reviewed studies have demonstrated that xylitol can reduce S. mutans levels and inhibit acid production. However, effective dosages in published research typically range from 5 to 10 grams daily — spread across multiple exposures. The amount of xylitol in a single DentaBiome tablet is not individually disclosed on the label.

Purple Carrot Powder: A source of anthocyanin antioxidants. Published research on anthocyanins has explored anti-inflammatory and antibacterial properties, though most published evidence involves concentrated extracts tested under laboratory conditions rather than the amounts present in a multi-ingredient chewable supplement.

Cranberry Extract: Cranberry-derived compounds — particularly proanthocyanidins — have been studied for their ability to interfere with bacterial adhesion. Published research has examined cranberry extract’s effects on oral biofilm formation, though effective concentrations and delivery methods vary across studies.

A recurring consideration in this category is whether a product publishes a fully detailed Supplement Facts panel with individually disclosed ingredient amounts. In DentaBiome’s case, the product materials do not appear to provide individual dosages for each ingredient. Without that level of disclosure, consumers and healthcare providers cannot directly compare what the product delivers against the specific amounts used in published research studies.

How Proprietary Formulations Affect Research Comparison

When a supplement uses a proprietary blend or does not individually disclose dosages, it allows the manufacturer to list which ingredients are included without revealing exact amounts for each one. This protects formulation trade secrets but limits a consumer’s ability to evaluate whether individual ingredients are present at research-supported levels.

For context, published xylitol research for oral health effects typically uses 5-10 grams daily. Published L. rhamnosus studies have used defined colony-forming units at specific concentrations. Cranberry proanthocyanidin research typically specifies the concentration of active compounds.

Without individually disclosed dosages on the label, there is no way to confirm or rule out research-level dosing from the product information alone. This is not unique to DentaBiome — many supplements use similar structures. But understanding how they work helps set realistic expectations when marketing materials reference published studies conducted at specific, known dosages or concentrations.

The “30-Second Kitchen Method”: What This Marketing Phrase Refers To

DentaBiome’s marketing frequently uses the phrase “30-second kitchen method” to describe the product’s use case. In practical terms, this refers to chewing the Berry Frost-flavored tablet once daily — a process that takes approximately 30 seconds.

The “kitchen method” framing is a consumer-facing marketing phrase designed to position the supplement as a simple daily habit rather than a complex regimen. The rationale for the chewable format — rather than a traditional capsule — is that chewing releases the postbiotic compounds directly into the oral cavity where they can contact tooth surfaces, gum lines, and other areas where harmful bacteria reside, rather than being dissolved in the stomach.

The concept of oral delivery for oral health ingredients has scientific merit. Research on oral probiotics and postbiotics has generally supported the idea that direct oral exposure may be preferable for targeting the oral microbiome compared to gastrointestinal delivery. However, no published clinical trial has tested DentaBiome’s specific chewable format against a capsule version to confirm a meaningful difference in oral health outcomes.

How Clinical Evidence for Supplement Effectiveness Is Typically Established

A recurring issue in supplement-category research is what level of evidence has been established for a finished product, and that question applies broadly across this category, not just to DentaBiome.

For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard generally includes a randomized, placebo-controlled trial using the finished product at its actual dosage. The study would need to disclose the exact formulation, specify the duration of use, define measurable endpoints such as changes in oral bacteria counts, gum health indices, or cavity incidence, and enroll a study population representative of the target consumer.

Results would typically be published in a peer-reviewed journal and subject to independent scrutiny. Ideally, a second independent study would replicate the findings to strengthen confidence in the conclusions.

As of this writing, no published clinical trial appears to have evaluated DentaBiome as a finished proprietary formula using this standard. The research cited on the product website pertains to individual strains or compounds tested in isolation or under laboratory conditions, often at dosages or concentrations that may differ from what the product delivers. That is common across the supplement industry, but it means the gap between ingredient-level research and product-level proof remains open.

Understanding this distinction is not about dismissing any product. It is about knowing exactly what has and has not been demonstrated so consumers can interpret the available evidence landscape rather than relying solely on how marketing materials frame it.

DentaBiome Pricing and Purchase Structure

DentaBiome is presented in multi-bottle packages through the official website:

The 6-bottle option (180-day supply) is listed at $49 per bottle ($294 total), includes two free bonus digital guides and free US shipping. This is described as the most popular option.

The 3-bottle option (90-day supply) is listed at $69 per bottle ($207 total) and includes the two free bonus guides.

The 2-bottle option (60-day supply) is listed at $79 per bottle ($158 total).

All purchases are one-time payments with no auto-ship, subscriptions, or hidden charges. The bonus guides included with multi-bottle packages are supplementary oral health resources covering at-home oral care techniques.

Pricing and availability can change, so consumers should verify current terms by viewing the current DentaBiome offer (official DentaBiome page).

DentaBiome Refund Policy and 60-Day Guarantee

DentaBiome orders are covered by a 60-day money-back guarantee. Consumers who are unsatisfied within the first 60 days of purchase can request a full refund by contacting the support team.

Bottles — even empty ones — should be returned to the Tallmadge, Ohio address. After processing a refund request, confirmation is sent via email. Refund timelines depend on the buyer’s payment method and financial institution.

Refund requests may be initiated through ClickBank’s self-service portal or through DentaBiome’s support email at support@getdentabiome.com.

DentaBiome Testimonials: What Consumers Should Know

The official website includes customer testimonials describing outcomes such as changes in gum bleeding, breath freshness, cavity occurrence, and gum pain. These testimonials are attributed to named individuals and labeled as “Verified Purchase.” Testimonials reflect individual experiences and are not considered clinical evidence.

The DentaBiome Terms and Conditions page includes a testimonial disclosure that provides additional context. The terms state that testimonials are individual experiences, that results vary, and that testimonials are not necessarily representative of all users. The terms further state that images or names used may have been changed to protect privacy.

The Terms also explicitly state that testimonials are not intended to make claims that these products can be used to diagnose, treat, cure, mitigate or prevent any disease, and that claims have not been clinically proven or evaluated by the FDA.

Even where testimonials reference specific health improvements, the published terms state these are individual experiences and not representative of typical outcomes. Consumers should factor these disclosures into how they interpret testimonial-based content on the product website.

Common Research Considerations in the Oral Supplement Category

Individually disclosed ingredient dosages. Individually disclosed ingredient dosages are one of the recurring research considerations in this category. When exact amounts are not disclosed on public-facing materials, consumers may seek clarification from the manufacturer through the published contact channels.

Ingredient research vs. product research. Published studies on individual postbiotic strains, xylitol, and cranberry extract were conducted under specific laboratory or clinical conditions. Consumers researching this category frequently encounter ingredient-level findings referenced in product marketing — understanding that these studies did not test the finished proprietary formula helps set realistic expectations.

FabM research context. FabM gene deletion research involved genetic engineering of bacteria in laboratory settings. Consumers researching this mechanism often encounter the 10,000x vulnerability figure, which refers to outcomes from gene knockout studies — not from testing any dietary supplement in a human oral environment.

Testimonial disclosures in the terms of service. The fine print on many supplement websites contains information about whether results are typical and whether names or images may have been changed in marketing materials. These disclosures are part of the background information consumers may encounter when reviewing supplement marketing materials.

Refund terms and guarantee conditions. Guarantee terms, return requirements, and processing timelines are part of the publicly available purchase and return information associated with the product.

Professional dental or medical input. Adults managing active periodontal disease, taking prescription medications, or undergoing dental treatment commonly consult a healthcare provider before adding any oral supplement to their routine.

How DentaBiome Is Positioned Within the Oral Supplement Category in 2026

DentaBiome is marketed toward adults exploring postbiotic-based oral health support as one component of a broader routine that may also include regular brushing, flossing, and professional dental care. Consumers conducting their own category research can review current product details by viewing the current DentaBiome offer (official DentaBiome page).

Consumers prioritizing fully disclosed ingredient amounts for research comparison, treatment for active dental disease, or products intended to replace professional dental care may interpret the product differently depending on their individual needs and expectations.

As with any dietary supplement, individual outcomes depend on a wide range of personal health factors. Supplements are regulated differently from pharmaceutical drugs, and the FDA does not evaluate dietary supplement claims for efficacy before products reach the market. The standard FDA disclaimer that applies to all dietary supplements confirms that the product’s statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Consumer Questions About DentaBiome

What is the “30-second kitchen method”?

The “30-second kitchen method” is a consumer-facing marketing phrase used on the DentaBiome website. It refers to chewing one DentaBiome tablet daily — a process that takes approximately 30 seconds. The phrase itself is not a recognized dental protocol or scientific method.

Is DentaBiome FDA approved?

DentaBiome is a dietary supplement. Under current federal regulations, dietary supplements do not require FDA approval before being sold. The FDA does not evaluate supplement efficacy claims. DentaBiome is manufactured in an FDA-registered, GMP-certified facility, which relates to manufacturing standards rather than product approval.

What is the FabM acid-lock?

As used in DentaBiome’s marketing, the “FabM acid-lock” describes a proposed mechanism where the FabM enzyme creates a protective shield around harmful oral bacteria, allowing them to survive despite brushing, flossing, and mouthwash. FabM is a real enzyme studied in published research at the University of Rochester, and its role in S. mutans acid tolerance has been demonstrated in laboratory settings. However, the specific framing as an “acid-lock” that a supplement can “break” is marketing language rather than a term used in published scientific literature.

What are postbiotics, and how are they different from probiotics?

Postbiotics are non-living compounds derived from beneficial bacteria — including antimicrobial peptides, enzymes, and organic acids. Unlike probiotics, which are live microorganisms, postbiotics are already produced and fully stable. Published research has explored postbiotic applications for oral health with promising early results, though most evidence comes from laboratory studies rather than large-scale human clinical trials.

Can I verify the research DentaBiome references?

The official website lists scientific references at the bottom of the sales page, including citations from PubMed and other research repositories. These citations point to published studies on oral microbiome research, postbiotic effects on dental caries, and enzymatic treatment of biofilms. These studies can be looked up through PubMed or the relevant journal archives. The referenced studies examined specific strains, compounds, or mechanisms under controlled research conditions — not DentaBiome’s proprietary formula as a finished product.

How long does DentaBiome take to show results?

The DentaBiome FAQ suggests using the product for at least 3 to 6 months as part of its marketed usage timeframe. The Terms and Conditions clarify that testimonial results are individual experiences and not representative of typical outcomes. Individual timelines depend on factors including baseline oral health, dietary habits, and consistency of use.

Is DentaBiome safe?

DentaBiome contains postbiotic compounds rather than live bacteria, which is presented as a distinguishing feature of the formulation. The product is described as vegan, gluten-free, soy-free, non-GMO, and free from major allergens. However, individual reactions to any supplement can vary. Consumers with existing health conditions, allergies, or those taking medications should consult a healthcare provider before use.

What is the DentaBiome refund process?

The published policy provides a 60-day window for refund requests. Refunds can be initiated through DentaBiome’s support email (support@getdentabiome.com) or by calling 1 (814) 885-4823 (Monday through Friday). Returns should be sent to Adem Naturals, 285 Northeast Ave, Tallmadge, OH 44278. Refunds can also be initiated through ClickBank’s self-service portal.

Where is DentaBiome sold?

DentaBiome is available through the official website at getdentabiome.com. Purchases are processed through ClickBank. Free US shipping is included with the 6-bottle package, with international shipping available to select countries for an additional fee.

Contact Information

Company: DentaBiome (Adem Naturals)

Return Address: 285 Northeast Ave, Tallmadge, OH 44278

Email: support@getdentabiome.com

Phone: 1 (814) 885-4823 (Monday through Friday)

Payment Processor: ClickBank (Click Sales Inc.)

Self-Service Billing Support: www.clickbank.com/corp/support/

For questions about the product, ordering process, or shipping, DentaBiome’s support team can be reached through any of the channels listed above. Complete product details, current pricing, and published terms are available by viewing the current DentaBiome offer (official DentaBiome page).

Disclaimers

Content and Consumer Information Disclaimer: This article is an informational overview and does not constitute medical, health, dental, or dietary advice. All product details, ingredient information, pricing, and policy terms described in this article are based on publicly available information from the official DentaBiome website and product labeling. Readers are encouraged to verify all details directly and to consult a qualified healthcare professional or dentist before beginning any dietary supplement.

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or dentist before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical and Dental Disclaimer: This article is educational and does not constitute medical or dental advice. DentaBiome is a dietary supplement, not a medication or dental treatment. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are undergoing dental treatment, consult your physician or dentist before starting DentaBiome or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your healthcare provider’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline oral health condition, dietary habits, oral hygiene practices, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. People who write reviews are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences.

FTC Affiliate Disclosure: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. ClickBank serves as the authorized payment processor for this product. ClickBank’s role as retailer does not constitute an endorsement, approval, or review of this product or any claim, statement, or opinion used in its promotion. This compensation does not influence the accuracy, neutrality, or integrity of the information presented.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were accurate at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing and terms on the official DentaBiome website before making a purchase.

Publisher Responsibility: Every effort has been made to ensure accuracy at the time of publication. Readers are encouraged to verify all details directly with DentaBiome and their healthcare provider before making decisions.

CONTACT: Email: support@getdentabiome.com
Phone: 1 (814) 885-4823 (Monday through Friday)

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting




Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

• New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21
• Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC)
• New ADC candidates, including ZW437 and ZW418, demonstrate strong activity across RAS-mutated cancers based on a novel pan-RAS inhibitor ADC platform

VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego, CA.

“We are excited to share new clinical and preclinical updates at AACR that highlight the breadth of our ADC portfolio and the continued evolution of our platform technologies,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “In addition to new preclinical combination insights from our ADC candidate ZW191, we will present data from our emerging RAS inhibitor ADC platform and several novel candidates designed to target treatment of RAS mutated cancers, some of the most prevalent oncogenic-driven human cancer types. Together, these findings demonstrate our differentiated approach to ADC design and our commitment to developing innovative therapies for patients with difficult-to-treat cancers.”

Oral Presentation Details

Title: Results from Part 1 dose escalation of ZWI-ZW191-101 study: Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)–targeting antibody-drug conjugate (ADC), in participants with advanced solid tumors
Abstract: CT306
Session: Advances in Precision Oncology
Date/Time: Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST)

“We look forward to presenting additional clinical data from Part 1 of our Phase 1 trial of ZW191, our FR alpha targeting ADC with our proprietary topoisomerase 1 inhibitor payload, in patients with advanced solid tumors,” said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer of Zymeworks. “The more mature results build on the initial data we presented at the AACR-EORTC-NCI conference in October 2025 and further reinforce our confidence in the potential ZW191 to be a well-tolerated and effective agent that is potentially best-in-class for patients with advanced, heavily pretreated cancers. We remain excited to advance ZW191 through the ongoing Part 2 of our Phase 1 trial and to explore strategic opportunities that could help maximize the potential of this program for patients.”

Poster Presentation Details

Title: ZW191 – a differentiated FRα-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs
Abstract: 7500
Session: Experimental and Molecular Therapeutics
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

ZW191 is a clinical-stage ADC targeting folate receptor alpha (FRα), currently under investigation in patients with advanced ovarian, endometrial, and non-small cell lung cancers (NSCLC). New preclinical data demonstrate strong anti-tumor activity when ZW191 is combined with standard-of-care agents, including carboplatin, paclitaxel, bevacizumab, and PARP inhibitors, driven by enhanced DNA damage in tumor cells. Together with encouraging early clinical data highlighting ZW191’s single-agent activity and differentiated safety profile, the findings support its potential to deliver meaningful efficacy improvements across multiple cancer types and treatment settings.

Title: A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers
Abstract: 5140
Session: Experimental and Molecular Therapeutics
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

A novel ADC platform has been developed to overcome the efficacy and tolerability limitations of current oral pan-RAS inhibitors, which despite clinical promise are associated with on-target toxicities in normal tissues. The platform incorporates newly synthesized pan-RAS inhibitor payloads demonstrating higher potency than the clinical benchmark RMC-6236, with optimized drug-linkers showing strong tumor regressions at low doses and no significant toxicity at high doses in preclinical models. These findings establish a highly promising pan-RASi ADC platform with the potential to deliver improved efficacy and tolerability across multiple RAS-driven cancers, including NSCLC, pancreatic, and colorectal cancer.

Title: Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer
Abstract: 4944
Session: Experimental and Molecular Therapeutics
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

ZW418 is a novel biparatopic ADC targeting PTK7, a protein broadly overexpressed in NSCLC, and delivering a novel pan-RAS inhibitor payload designed to improve upon the efficacy and tolerability limitations of current RAS inhibitors. Preclinical data demonstrate superior internalization and tumor penetration compared to clinical benchmark PTK7-targeted antibodies, alongside potent and targeted tumor cell killing and strong anti-tumor activity across multiple RAS-mutated cancer models. These findings support ZW418’s potential as a highly differentiated therapeutic for NSCLC patients whose tumors are driven by RAS mutations.

Title: ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers
Abstract: 7715
Session: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026 at 9:00 am – 12:00 pm PST

ZW427 is a novel ADC targeting Ly6E, a protein broadly overexpressed across multiple solid tumors, and delivering a novel pan-RAS inhibitor payload designed to improve upon the efficacy and tolerability limitations of current small molecule RAS inhibitors. Preclinical data demonstrate ZW427’s potent and targeted tumor cell killing, strong bystander activity, and anti-tumor activity across multiple RAS-mutated cancer models including NSCLC, pancreatic, and colorectal cancers. These findings support ZW427’s potential as a highly differentiated therapeutic for the large population of cancer patients whose tumors are driven by aberrant RAS signaling.

Title: ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer
Abstract: 4456
Session: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026 at 2:00 – 5:00 pm PST

ZW439 is a novel ADC targeting Claudin 18.2 (CLDN18.2) and delivering a novel pan-RAS inhibitor payload, designed to address the urgent unmet need in pancreatic cancer. Preclinical data demonstrate ZW439’s potent and targeted tumor cell killing across a range of CLDN18.2 expression levels, strong bystander activity, and highly efficacious anti-tumor activity in multiple cancer models, alongside an encouraging tolerability profile. These findings support ZW439’s potential as a differentiated therapeutic for patients with pancreatic cancer and other difficult-to-treat tumors driven by RAS mutations.

Title: Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads
Abstract: 2062
Session: Chemistry
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

A novel ADC platform has been developed incorporating newly synthesized eIF4A inhibitor payloads, which block translation of key oncogenic proteins including MYC and KRAS, offering a differentiated mechanism with the potential to address resistance seen with other ADC payload classes. Preclinical data demonstrate potent and targeted tumor cell killing in vitro and promising anti-tumor activity across multiple clinically relevant targets in vivo, including HER2, Ly6E, TROP2, and EGFR.

The AACR abstracts are available at https://www.abstractsonline.com/pp8/#!/21436.

Invited Talks

Senior members of Zymeworks’ research team will be speaking at the following sessions:

Title: Unlocking novel biologies with bi- and trispecific antibodies: the importance of antibody format
Speaker: Dr. Nina Weisser, Senior Director, Preclinical Multispecific Antibody Therapeutics
Date/Time: Wednesday, April 22, 2026 at 2:00 – 5:00 pm PST

Title: The (r)evolution of antibody-drug conjugates: From early concepts to next-generation cancer therapy
Speaker: Dr. Raffaele Colombo, Director, Medicinal Chemistry
Date/Time: Wednesday, April 22, 2026 at 8:32 – 8:59 am PST

About ZW191
ZW191 is an antibody-drug conjugate engineered to target a protein called folate receptor-⍺ found in ~75% of high-grade serous ovarian carcinomas¹ and ~70% of lung adenocarcinomas². ZW191’s differentiated design strongly supports its ability to internalize into FR⍺-expressing cells with the potential to release bystander active topoisomerase-1 inhibitor (ZD06519), a novel proprietary payload developed by Zymeworks to kill tumor cells.

ZW191 is currently being evaluated in a Phase 1 clinical study to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in participants with advanced solid tumors (NCT06555744). The study is designed to further characterize ZW191’s clinical activity and safety to inform its future development strategy.

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ implementation of its long-term strategy to maximize value creation; Zymeworks’ preclinical and clinical development of product candidates and enrollment in clinical trials; the timing and status of ongoing and future studies and the related data; anticipated preclinical and clinical data presentations; potential safety profile and therapeutic effects of Zymeworks’ product candidates; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful shareholder returns; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

¹ Köbel, M., Madore, J., Ramus, S. et al., Br J Cancer 111, 2297–2307 (2014).
² O’Shannessy DJ, et al., Oncotarget. 2012 Apr; 3(4):414-25.

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting




ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, have been accepted for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. All regular abstracts are available for viewing via AACR’s online itinerary planner located here.

Poster presentations details:

Abstract Highlights
Rinzimetostat is a potent and highly selective next-generation allosteric PRC2 inhibitor targeting the EED subunit that has demonstrated potential best-in-class efficacy and safety in a dose exploration trial in combination with androgen receptor (AR) inhibitors. To further evaluate the possible benefits of inhibiting PRC2 activity through EED targeting, preclinical studies investigated rinzimetostat versus EZH2- or EZH1/2-targeting agents in the context of proposed acquired resistance mechanisms. Biochemical assays demonstrated that rinzimetostat maintained potent inhibition of PRC2 complexes containing either EZH1 or EZH2 as the enzymatic subunit, while EZH2 or EZH1/2 dual inhibitors showed reduced activity in EZH1-containing complexes. Consistent with the biochemical data, rinzimetostat retained antitumor activity in prostate cancer cells overexpressing EZH1, while EZH2 inhibitors mevrometostat and tazemetostat lost potency in this context. Rinzimetostat also maintained inhibition of H3K27me3 in prostate cancer cells expressing the clinically reported EZH2-inhibitor acquired resistance mutation EZH2 Y666N, while EZH2 inhibitors did not reduce H3K27me3. In addition, in prostate cancer cells expressing the acquired resistance mutation EED-H213R, which is associated with clinical resistance to dual EZH1/2 inhibition, rinzimetostat equally inhibited H3K27me3 in both mutant and wild-type settings, while an EZH1/2 inhibitor did not. Together, these data suggest that rinzimetostat, as an EED inhibitor, has the potential for superiority in resistance context of EZH1 overexpression, as well as in acquired resistance mutant contexts of EZH2 and EZH1/2 inhibitors. A global phase 1b trial of rinzimetostat in combination with AR inhibitors is ongoing in metastatic prostate cancer (NCT05413421).

Abstract Highlights
Rinzimetostat is a potent and highly selective next-generation allosteric PRC2 inhibitor targeting the EED subunit that has demonstrated potential best-in-class efficacy and safety in a dose exploration trial in combination with AR inhibitors. Transcriptome analyses of more than 1,000 prostate cancer patient samples spanning primary prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), and neuroendocrine prostate cancer (NEPC) revealed gene expression patterns driving prostate cancer progression. Pseudotime analysis of tumor transcriptomes highlighted the eventual reduction in AR expression, AR signaling and luminal identity during mCRPC that may reflect lineage plasticity and cell state reprogramming. Integrated analysis across treatment lines identified epigenetic regulators, including PRC2, whose activity signatures increase during disease progression and may contribute to tumor heterogeneity and resistance to androgen receptor pathway inhibitors (ARPIs), further supporting the rationale for PRC2 inhibition. Rinzimetostat in combination with the AR inhibitor darolutamide demonstrated antitumor activity across a broad spectrum of in vivo prostate cancer models representing the treatment continuum, including castration-sensitive and castration-resistant disease, ARPI-sensitive and ARPI-resistant settings, and tumors harboring both AR-mutant and AR wild-type backgrounds. Together, these findings suggest that targeting PRC2 with rinzimetostat re-sensitizes ARPI-resistant tumors to AR pathway inhibition and blocks prostate tumor adaptation. A global phase 1b trial of rinzimetostat in combination with AR inhibitors is ongoing in metastatic prostate cancer (NCT05413421).

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 and EGFR PACC mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of rinzimetostat (ORIC-944); the potential advantages of rinzimetostat; clinical outcomes, which may materially change as patient enrollment continues or more patient data become available; statements regarding the potential best-in-class properties of rinzimetostat; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on February 23, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update




Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential

During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany’s BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer

The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated by the end of Q1 2026

Grand Cayman, Cayman Islands, March 17, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent business developments.

Recent Milestones & Business Highlights

Expanding Preclinical Validation Across KRAS-Driven Cancers: Throughout 2025, Silexion generated additional preclinical data supporting the broad therapeutic potential of SIL204. In human KRAS-mutated cancer cell line models, SIL204 demonstrated very high inhibition levels of cancer cell growth across multiple models and showed activity against eight distinct KRAS mutations: G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D. Preclinical efficacy was observed across four cancer types, including pancreatic, colorectal, lung, and gastric cancers. In orthotopic pancreatic cancer models, systemic administration of SIL204 resulted in significant reductions in primary tumor growth and metastatic spread to secondary organs.

Completion of Toxicology Studies and Clinical Trial Infrastructure Build-Out: In the fourth quarter of 2025, the Company completed two-species GLP toxicology studies for SIL204, supporting planned regulatory submissions and Phase 2/3 clinical readiness. During the year, Silexion also announced it has engaged AMS Advanced Medical Services GmbH as contract research organization (CRO) for its planned Phase 2/3 program and advanced manufacturing and operational partnerships to support scaled clinical execution.

Regulatory Advancement Toward Phase 2/3 Initiation: Silexion received written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) regarding the design of its planned Phase 2/3 clinical trial. The Company subsequently submitted its Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer and anticipates receiving initial regulatory feedback in the first quarter of 2026. The Company also plans to submit a Phase 2/3 clinical trial application in Germany by the end of the first quarter of 2026, with additional regulatory filings across the European Union planned in early 2027.

Strengthened Financial Position and Nasdaq Compliance: During 2025, the Company raised over $18.6 million in aggregate gross proceeds through public offerings and warrant exercises transactions. In September 2025, Nasdaq confirmed that Silexion had regained full compliance with Listing Rules 5550(a)(2) and 5550(b)(1), securing continued listing on the Nasdaq Capital Market.

Phase 2/3 Clinical Trial Planned for the Second Quarter of 2026: The planned Phase 2/3 clinical study is expected to begin in the second quarter of 2026 and will include an initial safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of approximately 166 patients. The study is designed to evaluate SIL204’s dual-route administration approach in combination with standard chemotherapy in patients with locally advanced pancreatic cancer.

Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “We made meaningful progress during the fourth quarter and throughout 2025 as we executed across scientific, operational, and regulatory priorities to advance SIL204 toward the clinic. With our toxicology package completed, written Scientific Advice from Germany, and the submission of our Phase 2/3 clinical trial application in Israel, we believe we are well-positioned to continue advancing toward our planned Phase 2/3 clinical program initiation in 2026. We remain focused on disciplined execution as we work to bring an RNAi-based approach to patients with KRAS-driven cancers.”

Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During 2025, we strengthened our financial position while maintaining a determined operating approach. We ended the year with approximately $6.0 million in cash and cash equivalents, and we believe our capital structure and focus on clinical progress support our planned development and regulatory and clinical milestones as we advance SIL204.”

Financial Results for the Three Months Ended December 31, 2025

• Research and development (“R&D”) expenses for the three months ended December 31, 2025, were approximately $3.4 million, compared to approximately $0.9 million for the same period in 2024.This quarter-over-quarter increase primarily reflected the Company’s continued progression toward clinical readiness, including increased development and external program execution activities.
• General and administrative (“G&A”) expenses for the three months ended December 31, 2025, were approximately $1.0 million, compared to approximately $1.0 million for the same period in 2024.
• Net loss for the three months ended December 31, 2025, was approximately $4.4 million, compared to approximately $1.7 million in the same period of 2024.

Financial Results for the Year Ended December 31, 2025:

• R&D expenses for the year ended December 31, 2025, were $7.1 million, compared to $5.8 million for the year ended December 31, 2024. The increase was primarily driven by higher subcontractor and consultant expenses related to GMP production batches of the active pharmaceutical ingredient (API) and formulation development intended to support initiation of the planned human clinical trial expected in the second quarter of 2026, partially offset by the absence of non-cash share-based compensation expenses recognized in the prior-year period in connection with grants issued during the August 2024 Business Combination.
• G&A expenses for the year ended December 31, 2025, were $4.5 million, compared to $6.8 million for the year ended December 31, 2024.The decrease primarily reflecting the absence of significant non-cash share-based compensation expenses and transaction costs recognized in the prior-year period in connection with grants issued during the August 2024 Business Combination, partially offset by higher professional services costs including director compensation, legal and other expenses associated with the transition to a public company subsequent to the Closing of the Business Combination, and more.
• Net loss for the year ended December 31, 2025, was $11.9 million, compared to a net loss of $16.5 million for the year ended December 31, 2024.

Balance Sheet Highlights:

• As of December 31, 2025, the Company had cash and cash equivalents of $6.0 million, compared to $1.2 million as of December 31, 2024. The Company believes that its current cash balance will support in its continued advancement toward the initiation of Phase 2/3 clinical trial expected in the second quarter of 2026.
• Total shareholders’ equity was $2.6 million as of December 31, 2025, compared to a capital deficiency of $(4.0) million as of December 31, 2024. During 2025, the Company completed multiple financing transactions, including approximately $11.0 million in gross proceeds from public offerings in January and September, approximately $2.6 million from warrant exercises, and approximately $5.0 million from warrant exercise inducement transactions (before related issuance costs).

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Notice Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, Including, for example, statements regarding the development of SIL204; the timing, content, outcome, and review of regulatory submissions and interactions with regulatory authorities in Israel, Germany, the European Union, and other jurisdictions; the timing, initiation, design, and conduct of the planned Phase 2/3 clinical trial (including the timing of patient enrollment and dosing) and any other clinical studies; the timing and results of additional preclinical, toxicology, manufacturing, and operational readiness activities; the potential therapeutic benefits, mutation coverage, and clinical utility of SIL204 and any future product candidates across multiple cancer types; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements; and Silexion’s ability to maintain its Nasdaq listing, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion’s ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion’s ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

SILEXION THERAPEUTICS CORP
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share data)

SILEXION THERAPEUTICS CORP
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share data)

<sup>All share amounts have been retroactively adjusted to reflect a 1-for-15 reverse share split as discussed in Note 1(e) of the Company’s financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025
* Represents an amount less than $1
** Net of 28 treasury shares held by the Company as of December 31, 2024</sup>

SILEXION THERAPEUTICS CORP
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share data)

^{* All share amounts have been retroactively adjusted to reflect a 1-for-15 reverse share splits as discussed in Note 1(e) of the Company’s financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025}

Compass Health Invites Community to “Camp Out” for Youth Behavioral Health




Compass Health Invites Community to “Camp Out” for Youth Behavioral Health

Annual fundraiser supports programs for children, youth, and families across Northwest Washington

EVERETT, Wash., March 17, 2026 (GLOBE NEWSWIRE) — For fifteen years, Compass Health has hosted therapeutic camps that help youth across Northwest Washington build confidence, strengthen social skills, and experience the joy of the outdoors.

Now, the community is invited to share in that same spirit of connection and fun at The Great Compass Health Camp Out, the organization’s annual fundraiser supporting its child, youth, and family programs. The event, which takes place April 17, 2026, at 6 p.m. at Thomas Family Farm in Snohomish, will be an evening inspired by the joys of the camp experience. The event is for guests 21 and older. Tickets are available online here.

“Our camps are about more than just outdoor fun,” said Tom Sebastian, CEO of Compass Health. “They give kids a chance to try new things, develop friendships, and experience the kind of connection that can change the trajectory of their lives. The Camp Out will celebrate those moments while supporting the broader network of child, youth, and family programs at Compass Health that serve young people and their families year-round.”

The Great Compass Health Camp Out marks the return of Compass Health’s signature annual fundraiser following the organization’s decision to reimagine its longstanding gala, previously known as the Building Communities of Hope Gala.

With a fresh format and a relaxed, camp-inspired atmosphere, this year’s event will feature nostalgic games and activities, classic camp treats, and opportunities to hear firsthand about the broad impact of Compass Health’s youth programs, which serve more than 6,000 Northwest Washington community members every year.

An event highlight will be the Mission Moment, a fireside-style conversation between Compass Health CEO Tom Sebastian and individuals who have directly benefited from the organization’s child, youth, and family programs, including a client, a caregiver, and a peer counselor. Together, they will share firsthand perspectives on how these programs support young people and families and the difference they are making in communities across the region.

Additionally, guests will be able to enjoy arcade favorites like Pac-Man, test their skills at Skee-Ball and mini golf, capture memories at the Camp Out photo booth, and purchase event-branded merchandise, including custom-pressed T-shirts and sweatshirts. The evening will feature a raffle and a raise-the-paddle fundraising opportunity, led by longtime host Fred Northrup Jr.

“Across the communities we serve, we continue to see youth behavioral health needs growing, and time and again we hear from community members asking how they can help,” said Tom Kozaczysnki, chief advancement officer at Compass Health. “The Camp Out is a chance to turn that goodwill into action – an evening for people to come together, have fun, and help ensure essential programs remain available to the young people and families who need them most.”

The Great Compass Health Camp Out is a key funding source for Compass Health’s child, youth, and family services, including programs that support young people struggling with behavioral health challenges and family chemical dependency issues. Benefiting programs are:

• Child and Family Outpatient Programs, which provide an array of counseling and support services to children, youth, and families that may have emotional and/or behavioral health challenges.
• Children’s Intensive Services / Wraparound with Intensive Services (WISe), which supports children and their families in the least restrictive environment by honoring the family’s voice, choice, strengths, and natural supports.
• Camp Outside the Box, a camp specifically designed for children and youth in the WISe program that gives them a chance to participate in fun summer activities while also practicing their social skills with other kids in the program.
• The Child Advocacy Program (CAP), a program that provides therapeutic services to children and adolescents who have experienced physical or sexual abuse or witnessed a violent crime.
• YGo Youth Mobile Crisis Outreach Program, which meets youth where they are, whether at home, school, or other community settings, and provides crisis stabilization and short-term support for up to eight weeks.
• Camp Mariposa, a year-round addiction prevention and mentoring program for youth affected by substance use disorder of a family member that offers fun, traditional camp activities combined with education and support sessions led by mental health professionals and trained adult mentors.

The event is supported by the generosity of many organizations, including FRANSiS, Kaiser Permanente, and BNB Builders. Sponsorship opportunities are still available for companies looking to connect with like-minded community members invested in mental health.

At a time when behavioral health providers across Washington are facing uncertainty due to proposed Medicaid cuts, community support plays a critical role in sustaining these vital programs and services.

“This year is Compass Health’s 125th anniversary, and it’s fitting that we’re celebrating by returning to where our mission began – supporting children and families,” added Sebastian. “For more than a century, we’ve been committed to making sure young people in our communities have access to the care and support they need to thrive, and that commitment remains as strong as ever. We’re grateful for everyone who stands alongside us to support the next chapter of this work for generations to come.”

To learn more about The Great Compass Health Camp Out and purchase tickets, visit www.compasshealth.org/tgcco/. Tickets for the event close Tuesday, April 3.

About Compass Health:   
Compass Health is Northwest Washington’s behavioral healthcare leader. A community-based healthcare agency, Compass Health integrates behavioral health and medical care services to form a key section of the community safety net and serve clients and others in need of care and support. From comprehensive mental health treatment to crisis prevention and intervention, supportive housing, children’s services, community education and much more, the non-profit organization serves people of all ages throughout Snohomish, Skagit, Island, San Juan, and Whatcom counties.   
  
Media Contacts:   
McKenzie Morgan 
Firmani + Associates Inc.   
Compasshealth@firmani.com   
(702) 580-8687   
  
Sarah Forster 
Compass Health   
Sarah.forster@compassh.org 
(306) 728-8288

Virbac: 2025 annual results




Virbac: 2025 annual results

A robust adjusted EBIT margin² of 16.3% at CERS, driven by solid organic revenue growth of 7.9%

• Solid 2025 dynamic with annual revenue up +7.9% at CERS; with strong momentum in key categories and countries. Volume/mix effect of ~+5%, completed by price increase of ~+3%
• Adjusted EBIT (before amortization of assets arising from acquisitions) margin of 16.3% at CERS despite:
  • temporary shutdown of an antigen’s production site and higher inventory write-offs in FY25
  • partially offset by a solid underlying performance on sales prices and product mix and;
  • improving operating expense to revenue ratio. 
• Consolidated net income increased by +3.2% and amounts to €150.5m
• Strong cash generation of €93 million funded the Thyronorm acquisition while maintaining a relatively stable net debt at €172.8 million compared to €168.5 million at the end of 2024

• 2026 guidance: (incl. Thyronorm acquisition impact) : revenue growth expected to be between 5.5% and 7.5% at constant rates and scope. Adjusted recurring operating income¹ expected around 17%

¹Change at constant exchange rates and scope corresponds to organic sales growth, excluding exchange rate variations by calculating the indicator for the current and prior periods using identical exchange rates (the exchange rate used is that of the prior period), and excluding material changes in scope by calculating the indicator for the current period based on the prior period’s consolidation scope. This change is calculated on the actual scope, including scope impacts from acquisitions (Sasaeah company), for which the relevant indicator is calculated using the prior period’s exchange rate.

²EBIT Adjusted (before amortizations) corresponds  to “recurring operating income before amortization of assets arising from acquisitions”.

³Net debt corresponds to current (€105.9 million) and non-current (€150.4 million) financial liabilities, as well as the lease liability related to the application of IFRS 16 (€39.0 million), less cash and cash equivalents (€122.5 million) as published in the statement of financial position.

⁴Operating cash flow corresponds to the EBIT adjusted before amortizations of asset arising from acquisitions (€234.4 million) restated for depreciation & provisions (€56.4m – amortizations from acquisitions adjusted), non-cash items (€1.2m), impacts related to disposals (€1.1m) and other non-current income & expenses (-€4.1m).

The financial statements have been audited by the statutory auditors and were reviewed by the Board of Directors on March 17, 2026. The financial statements and the detailed presentation of the annual results are available on the corporate.virbac.com website.

Paul Martingell, Chief Executive Officer statement: 

“Our 2025 performance perfectly illustrates the resilience and agility of the Virbac teams and model. We delivered solid organic growth of 7.9% and maintained a robust adjusted EBIT margin of 16.3% (at constant exchange rates and scope), despite some temporary headwinds. This financial strength, characterized by a strong cash generation power and low debt, has allowed us to accelerate our strategic investments: we reached record levels in R&D to support future innovations as well as in Capex to bolster our industrial transformation. The acquisition of Thyronorm further highlights our ability to seize targeted external growth opportunities to complete our portfolio in high unmet need areas. In the face of a continued unstable external environment, we enter 2026 with confidence. Our diverse portfolio and the exceptional commitment of our teams allow us to look forward with confidence and to continue our mission of advancing animal health.”

Full year 2025 sales by geography

For the full year 2025, revenue reached €1,465 million, compared to €1,397 million in 2024, representing an overall increase of +4.8%. Excluding currency effects, revenue delivered significant growth of +8.7%. At constant exchange rates and scope, growth for FY25 stands at +7.9%. The acquisition of Sasaeah (Japan, April 2024) contributed +0.8 percentage points to growth. The acquisition of Mopsan (Türkiye, Dec 2024) contributed +0.4 points; however, this impact was not excluded from the constant scope calculation as it was deemed non-material.

• Europe (+7.5% at CERS): This strong organic growth was driven by positive momentum across all segments and geographies within the region. The Companion Animal business grew by 7.8%, supported primarily by our petfood, dermatology, and reproduction ranges. Meanwhile, the Farm Animal segment also recorded an 8.2% increase; this was largely due to the response to the bluetongue virus (BTV) epidemic and the solid performance of core ruminant products, though these gains were partially tempered by production delays impacting our antibiotic ranges.
• North America (+14.7% at CERS): The region once again delivered an exceptional performance, spearheaded by the Companion Animal segment (+24.2% at CERS). This growth was propelled by the combined success of new launches (specifically Ursolyx and Zenifel) and strong results from our core business, particularly in the dental, dermatology, and specialty ranges (mobility and behavior). However, this was partially counterbalanced by a decline in our contract manufacturing business (-33.5%), which faced delayed orders. It is worth noting that, excluding the impact of distributor destocking/restocking, organic growth for the region would stand at ~+12%. 

• Latin America (+7.4% at CERS): The Companion Animal segment posted a 13.0% increase at CERS, with Mexico (+19%) and Colombia (+23%) acting as the primary engines of growth. This performance was built on the success of our petfood, vaccine, dermatology, and nutritional portfolios. The Farm Animal segment also increased, driven by results in Brazil (+14.3%), Colombia (+33.4%), and Mexico (+4.8%). The main contributors to this segment were cattle vaccines, antibiotics, antiparasiticides, and nutritional products, partially offset by a downturn in Chile (-9.6%), where our aquaculture activities faced intensified competitive pressure. 

• IMEA (+9.5% at CERS): The zone delivered solid progress across all geographies, spearheaded by the Farm Animal segment (+10%). This strong growth was primarily sustained by our ruminant portfolio, with a particularly strong contribution from our nutritional products. Meanwhile, the Companion Animal segment also recorded a robust increase of +6.8%. 
• Far East Asia (+3.3% at CERS): The zone achieved growth across all geographies, except in Vietnam due to the swine fever epidemic. The Companion Animal segment grew +5.2%, supported by our specialty and antiparasiticides ranges. The scope effect from the acquisition of Sasaeah (completed in April 2024) contributed an additional 9.6 pt to the zone’s growth for the year.
• Pacific (+0.1% at CERS): The zone remained stable compared to the previous year. Australia recorded a slight decline (-1.6%), impacted by increasing competition and destocking activities at major distributors; however, a recovery was observed in the second half of the year, driven by improved market conditions, normalized inventory levels, and sustained demand in the Companion Animal segment. Conversely, New Zealand closed the year with solid growth of +5.7%, supported by the extension of our nutritional product range and increasing sales of antibiotics.

Full year 2025 results

EBIT Adjusted (before amortizations²) stood at €234.4 million in FY25 compared to €231.8 million in FY24
The actual margin reached 16.0% in FY25 compared to 16.6% in FY24. After adjusting for a currency effect of -0.5 point and a scope effect of +0.2 point, the margin at constant exchange rate and scope amounts to 16.3% in FY25. The performance in 2025 is explained by a decrease in the gross margin (-0.7 point) and by controlled operating and R&D expenses (+0.1 point).

• The decline in gross margin, beyond the impact of exchange rate is primarily attributable to two factors: a temporary production interruption for one of the Group’s antigens due to facility maintenance, with operations having since resumed and higher level of inventory write-offs compared to last year. However, this was partially offset by a very solid underlying performance fueled by favorable sales prices and product mix.  
• Operating expenses were managed efficiently in 2025 leading to the reduction of the ratio to revenues of 0.2 point.
• R&D expenses grew in value as expected but stayed relatively stable in ratio to revenues at ca. 7.9% in FY25 due to the strong revenue growth (0.1 point).

Consolidated net income amounts to €150.5 million, an increase of 3.2% compared to 2024

• Amortization charges on intangible assets from acquisitions increased from €4.3 million to €4.8 million, a rise mainly due to the integration of Mopsan (acquired in Dec24) and to a lesser extent Sasaeah (acquired in Apr24).
• Non recurring income and expenses stand at €3.5 million in 2025 and are mainly composed of provisions for depreciation of assets no longer in use (€2.4m) and one-off operational expenses mainly related to M&A activities (€1.8m).
• Net financial expense increased to €8.6 million, compared to €9.3 million in 2024, and mainly consists of a foreign exchange loss of €4.1 million, supplemented by a cost of financial debt of €4.3 million. The foreign exchange loss is due to the appreciation of the euro against unhedged exposures, particularly to the Chilean peso (-€2.2 million) and, to a lesser extent, the Mexican peso (-€1.9 million).
• Corporate income tax increased to €67.2 million compared to €62.5 million in 2024 in line with the level of activity. The effective tax rate has slightly increased to ~26.5% vs 25.5% in 2024 essentially linked to a country mix effect.
• Net income – Group share stands at €150.9 million, an increase of 3.9% compared to the previous year (€145.3 million).

Net debt as of Dec25, stands at €172.8 million relatively stable compared to Dec24 (€168.5m)
The operating cash flow before interest and taxes increased to 289m€. The capex spending amounted to 102m€ essentially linked to our industrial transformation including a few new sites being built to support the future growth of the group. Working capital requirements benefited from an improvement in our inventory and contributed positively to the net free cash flow. All of these elements resulted in a solid cash generation of €93 million at constant exchange rates and scope, which enabled the €107.8* million acquisition of Thyronorm in December 2025, leaving a relatively stable net debt level at the end of 2025 compared to 2024.

Key events of the period

• Paul Martingell is appointed CEO of Virbac Group, Effective September 1, 2025
• Virbac continues to execute its “programmatic M&A” strategy with the recent acquisition of Thyronorm. Thyronorm (~€27M in-market annual revenue) is a specialty product to treat feline hyperthyroidism, a condition affecting more than 10% of older cats. This addition complements the existing portfolio and is expected to be accretive to sales and EBITDA margin from Year 1. Virbac will distribute directly in the UK, Australia, and NZ (under Thyronorm) and in the US (under Felanorm). In Europe, distribution will transition from partners (Boehringer Ingelheim, Elanco) to Virbac over the coming years.

*Note: The €107.8m Thyronorm acquisition amount includes an €11.5m escrow payment. In accordance with our reporting standards, this is classified under other working capital rather than as a direct M&A investment.

Guidance 2026

For the year 2026, we currently anticipate at constant rate and scope :

• A revenue growth between 5.5% and 7.5%
• A ratio of “current operating income before amortization of assets resulting from acquisitions” (Ebit adjusted) to “revenue” around 17%
• Our cash generation should be around ~+€80m

In line with our reporting standards, the Thyronorm acquisition is included within the 2026 organic perimeter (constant scope) due to its materiality level. Consequently, the provided guidance accounts for Thyronorm’s contribution to both total revenue (~+1 pt of growth) and expected operating income (~+0.5 Ebit adjusted). As previously disclosed the direct impact of US tariffs is estimated as of today at approximately US$4 million annually. This impact is fully integrated into our 2026 outlook.

Finally, at the next shareholders’ meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year.

ANALYSTS’ PRESENTATION – VIRBAC

We will hold an analysts meeting on Wednesday, March 18, 2026 at 2:00 p.m. (Paris time – CET)
in the Sainte-Cécile auditorium, 8 rue Sainte-Cécile, 75009 Paris (France)

Participants may arrive 15 minutes before the start of the meeting.

You may also attend the meeting using the webcast (audio + slides) available via the link below.

Information for participants:

Webcast access link: bit.ly/3Pc4jdM

This access link is available on the corporate.virbac.com site, under the heading “Public releases.” This link allows participants to  
access the live and/or archived version of the webcast.

You will be able to ask questions via chat (text) directly during the webcast or after watching the replay via the following email 
address: finances@virbac.com.

 About Virbac – Caring for animals together

At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal pathologies. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together.

More information on corporate.virbac.com

ANNEXES

1. Income statement of the period

2. Statement of financial position

3. Statement of cash flow

4. Reconciliation tables for alternative performance indicators

1. 1. Net Debt 

1. 2. Operating cash flow before interest and taxes

Attachment

• Virbac – Press release – FY25 results

Naturonel Launches Made-in-USA Herbal Supplements to Support Metabolic Wellness




Naturonel Launches Made-in-USA Herbal Supplements to Support Metabolic Wellness

New line of plant-based dietary supplements tested for purity and potency now available to consumers nationwide.

Naturonel Image

PRINCETON, N.J., March 17, 2026 (GLOBE NEWSWIRE) — Naturonel, a wellness brand focused on herbal nutrition and metabolic wellness, announced the launch of its new line of plant-based dietary supplements manufactured in the United States and third-party tested for purity and potency.

As consumers increasingly seek transparent, responsibly manufactured wellness products, Naturonel’s newest supplements are designed to support everyday health, balanced energy, and metabolic wellness through carefully blended botanical ingredients, vitamins, and minerals.

“We are excited to officially launch this line of supplements to meet growing consumer demand for high-quality, plant-based wellness products,” said a spokesperson for Naturonel. “Our focus is on transparency, responsible manufacturing, and formulas that reflect both traditional herbal knowledge and modern quality standards.”

Made in the USA with a Focus on Quality

All Naturonel products are manufactured in U.S. facilities following Good Manufacturing Practice (GMP) standards. Each formula undergoes third-party testing to verify purity and potency, giving consumers confidence in the products they choose for daily wellness.

Herbal Inspiration Meets Modern Nutrition

Drawing from long-standing herbal wellness traditions, Naturonel combines botanical ingredients with vitamins and minerals to support metabolic balance and overall vitality. The supplements reflect both traditional herbal knowledge and current nutritional research, appealing to wellness-conscious consumers.

Product Availability

The newly launched supplements are available nationwide and can be purchased through the Naturonel website www.naturonel.com as well as Amazon product listings for convenience and accessibility.

Looking Ahead

Naturonel plans to continue expanding its supplement line with additional formulations designed to support a wide range of wellness needs. The company also emphasizes consumer education around ingredient sourcing, formulation, and quality standards.

About Naturonel

Naturonel is a wellness brand dedicated to developing dietary supplements inspired by herbal traditions and supported by modern nutritional science. Naturonel products are manufactured in the United States and third-party tested for purity and potency, with formulas designed to support metabolic wellness, balanced energy, and everyday vitality.

Media Contact:
Naturonel
800-430-5241
Email: hello@naturonel.com
Website: www.naturonel.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/036af245-1f4f-44ce-afa4-7678099d7b0e

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder




National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

• Jails outpace prisons in offering MOUD, but regional disparities and limited treatment access persist across the U.S.
• Qualitative feedback points to need for greater reentry support, housing, care coordination, and provider training

RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) — Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities.

Funded by Indivior and conducted in partnership with the National Commission on Correctional Health Care (NCCHC), the study surveyed 212 jails, prisons, and detention centers. Findings indicate that just 58% offer at least one FDA-approved MOUD and stark disparities in treatment access exist across regions and facility types.

The study found that jails were more than twice as likely to provide MOUD compared to prisons and that facilities in the West had over three-fold higher odds of offering MOUD than those in the Midwest. Regional disparities persist, with facilities in the South, Midwest and rural areas reporting the greatest uncertainty about care delivery. Despite increasing awareness of the benefits of MOUD, the South reports the lowest rates of treatment access, with fewer than 10% of diagnosed individuals receiving treatment. Midwest facilities report moderate levels of treatment for diagnosed individuals, some below 10%, while others report between 20%–29%.

“This study reinforces the urgent need to integrate evidence-based care into jails and prisons,” said Christian Heidbreder, PhD, Chief Scientific Officer at Indivior. “To truly address the opioid crisis, we must ensure continuity of care, expand access to medications for opioid use disorder, and eliminate the stigma that prevents people from receiving treatment during and after incarceration.”

Correctional settings are among the most critical intervention points for opioid use disorder (OUD) treatment: An estimated 17% of individuals in state prisons and 19% of those in jails meet the criteria for OUD.¹ Research shows that individuals in their first two weeks post-release from incarceration face overdose mortality rates that are up to 40 times higher than the national average.² MOUD treatment during incarceration can significantly reduce these risks and improve treatment retention.³

“With renewed national attention on strengthening addiction treatment and recovery, our study underscores both the opportunities and the challenges ahead,” said Vanessa Procter, Executive Vice President, Corporate Affairs at Indivior. “We’re encouraged to see recovery rising on the federal agenda, and these data offer a roadmap for expanding life‑saving care inside jails and prisons. Improving continuity of care—from incarceration to community—is not a partisan issue. It’s a public health imperative, and the evidence shows what works.”

_____________________________

¹ Medications for Opioid Use Disorder Save Lives | The National Academies Press
² Opioid Overdose Mortality Among Former North Carolina Inmates: 2000-2015, Table 1. (Graph: Maddy Troilo, 2018)
³ Medication for opioid use disorder service delivery in carceral facilities: update and summary report | Health & Justice | Full Text

In addition to quantitative findings, the survey captured qualitative insights from correctional health professionals on ideal infrastructure to support reentry and reduce reincarceration.

Respondents identified five critical areas for improving MOUD continuity and outcomes:

• Access to long-acting injectables and telehealth: Respondents called for greater investment in cost-effective medications, including funding for injectable treatments like extended-release buprenorphine and extended-release naltrexone, as well as telemedicine partnerships to extend care into rural settings.
• Continuity of care and transition services: Respondents emphasized the importance of pre-release planning and providing a warm handoff from incarceration to community-based MOUD services.
• Housing and employment: Respondents highlighted the role of transitional housing, job training, and financial stability in sustaining recovery.
• Comprehensive MOUD treatment approaches: Respondents advocated for “medical homes” that combine MOUD with mental health care, infectious disease treatment, and social support.
• Community support networks: Respondents pointed to the value of peer mentorship, recovery organizations, and community-based programs to promote engagement post-release and reduce re-incarceration.

Despite growing recognition of MOUD as the standard of care for OUD, many facilities cited persistent barriers to implementation, including stigma, abstinence-only philosophies, lack of provider training, limited budgets, and geographic disparities in healthcare infrastructure.

The full survey findings are available here: Medications for Opioid Use Disorder in Correctional Facilities: A 2022 Cross-Sectional Survey of Health Care Staff

About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

For Further Information

Investors:
Jason Thompson Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com

Media:
Cassie France-Kelly Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com

Personalized Keto Made Easy: How Ketoway Supports Consistent Results and Healthy Habits




Personalized Keto Made Easy: How Ketoway Supports Consistent Results and Healthy Habits

Ketoway Helps Users Achieve Lasting Keto Success with Personalized Meal Plans, Guided Workouts, and Transparent Customer Support

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — Ketoway is a personalized keto-diet app designed to deliver real, sustainable results through structured guidance, simple planning, and ongoing support. By combining tailored meal plans, light workouts, and progress tracking, it removes guesswork and helps users stay consistent with a low-carb lifestyle.

What Is Ketoway and How It Works
After a short onboarding quiz, Ketoway creates a customized program based on individual goals, preferences, and daily routine. Users receive a clear meal plan, easy-to-follow recipes, and guided workouts that fit into busy schedules. This structured approach makes keto accessible for beginners while still being effective for experienced users.

Proven Effectiveness Through Structure
Ketoway focuses on long-term results rather than quick fixes. Built-in trackers for weight, hydration, steps, and fasting provide a full picture of daily habits, helping users stay accountable and motivated. Combined with lifestyle challenges and educational content, the app supports steady progress, improved energy, and better overall wellness.

Clear Billing and Full Transparency
Ketoway stands out with straightforward, transparent billing practices. Subscription details, pricing, and renewal terms are clearly presented before purchase, so users know exactly what to expect. Managing or canceling a subscription is simple, ensuring full control without hidden conditions – an important factor for trust and user confidence.

Reliable and Responsive Customer Support
Customer support is a key strength of Ketoway. Users can expect fast, helpful, and friendly assistance with any questions related to plans, billing, or app features. This responsive customer support system ensures users stay focused on their progress rather than dealing with technical or account issues.

Ketoway Reviews From the Keto Community
Reddit users describe Ketoway as a keto app that truly sticks. Many highlight that the biggest advantage is eliminating decision fatigue – opening the app each day to find clearly defined meals and light workouts without having to guess what comes next. The built-in trackers support accountability, while guided workouts and lifestyle challenges make keto-diet approachable, manageable, and sustainable.

For those seeking a structured, practical, and lasting approach to a keto lifestyle, Ketoway provides a clear path to real results. A personalized plan can be started today, turning keto into a simple, consistent, and effective routine.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29e89794-47d5-4f95-a416-7e46d7b1a3b7

CONTACT: evita.anilionyte@flmng.ai 

SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas




SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas

RANCHO CORDOVA, Calif., March 17, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas.

The U.S. Food and Drug Administration (FDA) carried out a general inspection of the site from February 9 to February 12, 2026. After a thorough review of the facility’s quality systems and manufacturing operations, the FDA completed the inspection without issuing a Form 483. This “No Action Indicated” (NAI) status confirms that the site complies with the highest regulatory standards.

“The successful completion of this FDA inspection directly reflects the commitment to excellence and strong quality culture of our La Porte team,” said Kalen Minvielle, Head of Small Molecule, North America. “Maintaining an NAI status is a significant achievement that continues to highlight the strength of our systems and disciplined approach to building quality into every step of the process. It ensures our customers can continue to rely on SK pharmteco for secure, compliant, and uninterrupted manufacturing of life-enhancing medicines.”

The general inspection included thorough tours of the warehouse, manufacturing plant, and analytical laboratories. Inspectors conducted an in-depth review of the site’s procedural rigor, assessing batch records, Corrective and Preventive Actions (CAPAs), deviation and Out-of-Specification (OOS) investigations, and change controls. The agency also confirmed the integrity of the site’s equipment qualifications, purified water systems, and process and cleaning validations.

SK pharmteco actively partners with the FDA in the pursuit of excellence and continuous improvement. For example, the company recently participated in the FDA Quality Management Maturity (QMM) program, an initiative that recognizes drug manufacturers with advances beyond compliance and a culture of continuous improvement and reliability.

This successful inspection reinforces SK pharmteco’s global reputation for operational excellence in both small molecules and viral vectors, as well as its dedication to meeting the stringent requirements of regulatory agencies worldwide.

About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company’s core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market. Through these pillars, SK pharmteco supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

Contact:
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com